May 11, 2021 09:38 AM EDT
Pharma

Is re­mote work here to stay for bio­phar­ma? Ear­ly in­di­ca­tions point to yes

Max Gelman

Senior Editor

Covid-19 cas­es in the US have be­gun to ebb, fol­low­ing a na­tion­wide vac­ci­na­tion cam­paign that has near­ly 60% of Amer­i­can adults re­ceiv­ing at least one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times